YM150
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Venous Thromboembolism
Conditions
Venous Thromboembolism
Trial Timeline
May 1, 2009 → Apr 1, 2010
NCT ID
NCT01028950About YM150
YM150 is a phase 3 stage product being developed by Astellas Pharma for Venous Thromboembolism. The current trial status is completed. This product is registered under clinical trial identifier NCT01028950. Target conditions include Venous Thromboembolism.
What happened to similar drugs?
6 of 20 similar drugs in Venous Thromboembolism were approved
Approved (6) Terminated (3) Active (12)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01125670 | Phase 1 | Completed |
| NCT01125657 | Phase 1 | Completed |
| NCT01118559 | Phase 1 | Completed |
| NCT00937820 | Phase 3 | Completed |
| NCT00937911 | Phase 3 | Completed |
| NCT00942435 | Phase 3 | Completed |
| NCT01028950 | Phase 3 | Completed |
| NCT01657981 | Phase 1 | Completed |
| NCT00353678 | Phase 2 | Completed |
Competing Products
20 competing products in Venous Thromboembolism